CVSI
CV Sciences, Inc.0.0300
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.53MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Restructures notes, adds conversion
CV Sciences amended its secured notes on March 4, 2026, adding a $0.06/share conversion feature into 37.6M common shares while hiking aggregate principal 20% to $2.256M and axing monthly redemptions. This restructuring, amid prior default risks, eases cash burn yet ties assets as senior liens. Dilution looms large.
8-K
Q3 revenue falls 16%
CV Sciences reported Q3 2025 revenue of $3.3M, down 16% from $3.9M in Q3 2024 due to out-of-stock issues and state regulations, yet gross margins improved to 48.5% from 46.0%. Operating loss held steady at $0.3M while cash dipped to $0.4M. New Ignite launch expands +PlusCBD lineup. Hemp restrictions delayed one year.
10-Q
Q3 FY2025 results
CV Sciences posted Q3 product sales of $3.3M, down 16% y/y yet holding steady q/q, with gross margin expanding to 48.5% from 46.0% on lower freight and better mix despite Elevated Softgels and Cultured Foods costs. Operating loss narrowed to $0.3M from $0.3M y/y, while nine-month sales fell 11% y/y to $10.5M but operating loss shrank to $0.4M from $1.5M, boosted by $0.5M payroll tax reversal. Cash dipped to $381K amid $53K nine-month operating outflow; debt stood at $1.0M net with $0.5M long-term. Losses track across operating and net lines. New federal law bans hemp products over 0.4mg THC per container effective November 13, 2026.
8-K
Secures $600K note, nets $300K
CV Sciences issued a $600,000 secured note to an institutional investor on October 6, 2025, closing October 7, with net proceeds of $300,000 after $150,000 OID and $150,000 for modifying a prior note plus fees. The asset-secured note matures April 6, 2027, with monthly repayments of $46,153.85 starting April 6, 2026; no interest accrues absent default. All assets pledged, yet cash inflow stays lean.
8-K
Amends $1.6M note terms
CV Sciences amended its $1.6M secured note with an institutional investor on September 12, 2025, extending maturity to February 12, 2027, and restructuring redemptions: $106,666.67 monthly for first 3 and final 12 months, none for 6 months in between. Current balance stands at $1.28M after $320K payments. Investor gets $150K cash; additional $450K note funding follows.
IPO
Website
Employees
Sector
Industry
CBDL
CBD Life Sciences Inc.
0.00+0.00
CBIH
CANNABIS BIOSCIENCE INTERNATION
0.00-0.00
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CRLBF
Cresco Labs Inc.
1.75+0.45
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
OVATF
OVATION SCIENCE INC
0.03+0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
VEXTF
Vext Science Inc.
0.22+0.01
YCBD
cbdMD, Inc.
1.43+0.23